World News

GSK eyes ‘step change’ in shingles vaccine output in 2024

World

GlaxoSmithKline said further growth from its shingles vaccine, which has boosted earnings, would be reined in by limited capacity until 2024, but a new bioreactor facility would then be ready to bring a "step change" in production.

FILE PHOTO: The GlaxoSmithKline (GSK) logo is seen in Singapore, March 21, 2018. REUTERS/Loriene Perera/File Photo

Share this content

Bookmark

WAVRE, Belgium: GlaxoSmithKline said further growth from its shingles vaccine, which has boosted earnings, would be reined in by limited capacity until 2024, but a new bioreactor facility would then be ready to bring a "step change" in production.

GSK, Britain's largest drugmaker, had originally envisaged a gradual launch in the United States, its biggest market, but regulators unexpectedly recommended Shingrix not only for people reaching the age of 50 but also to replace an established product.

Advertisement

Advertisement

A bioreactor in Belgium that makes so-called antigens – proteins that trigger an immune reaction against the shingles virus – is reaching its capacity limits. A second one is in the works at an undisclosed location, but the complex facility takes time to build.

"The key project is the expansion of antigen bulRead More – Source

Related Posts